 1. Assess the safety and effect on myocardial function of MyoCellTM autologous skeletal myoblast using a dose escalation methodology following implantation into myocardial scar tissue of subjects with congestive heart failure who have experienced previous myocardial infarctions and have had an implantable cardioverter defibrillator ICD previously implanted. Safety endpoints will be the evaluation of the nature and frequency of Adverse Events during the 12-month period following MyoCellTM treatment. 